AN influential group with close ties to prime minister Narendra Modi's ruling Bharatiya Janata Party (BJP) has accused PepsiCo Inc of coercing four Indian farmers who have been sued by the US company for allegedly infringing a patent.
After suing four farmers for cultivating the FC5 potato variety, grown exclusively for PepsiCo's popular Lay's potato chips, the snack food and drinks maker last week said it wants to "amicably settle" the issue.
The Purchase, New York-based company said the four farmers had to either sell their potatoes to PepsiCo or stop cultivating the FC5 potato variety. In return, PepsiCo said it would withdraw the suit filed against the farmers.
Ashwani Mahajan, who heads the Swadeshi Jagran Manch, said PepsiCo was "coercing" the farmers by using legal action to force them to either sell their output to the company or to stop growing the FC5 potato variety at all.
SJM is the economic wing of Rashtriya Swayamsevak Sangh (RSS), the ideological parent of Modi's BJP.
The dispute comes at a particularly sensitive time in India, which is about half-way through a 39-day staggered general election, in which its rural population still has a dominant voice.
Modi and the BJP are seeking a second term and most political strategists think they will likely get it.
"Other than coercing these farmers, PepsiCo is also intimidating and exploiting them. It is a clear case of a large MNC (multi national corporation) arm-twisting India's poor farmers," Mahajan said.
The federal government should step in to ensure that the farmers do not get harassed by PepsiCo, he said.
In response, a PepsiCo India spokesman said in a statement that it "has already proposed to amicably settle with people who were unlawfully using seeds of its registered variety."
Adding: "The company was compelled to take the judicial recourse as a last resort to safeguard the larger interest of thousands of farmers that are engaged with its collaborative potato farming program."
The FC5 variety has a lower moisture content required to make snacks such as potato chips.
PepsiCo maintains that it developed the FC5 variety, which has a lower moisture content required to make snacks such as potato chips, and registered the trait in 2016.
In April, the company filed the lawsuit in a court in Ahmedabad, the business hub of Gujarat, requesting the court to retrain the four farmers from growing the FC5 variety.
The court has asked the farmers not to use the variety until the next hearing scheduled for June 12.
The court also appointed an officer to examine the issue.
Other than filing the lawsuit, the company has also sought more than Rs 10 million each from the four farmers for alleged patent infringement.
PepsiCo shouldn't have gone to the court seeking heavy damages from farmers and a large corporation cannot be allowed to take on a handful of farmers, Mahajan said.
PepsiCo, which set up its first potato chips plant in India in 1989, supplies the FC5 potato variety to a group of farmers who in turn sell their produce to the company at a fixed price.
The state government of Gujarat has assured the farmers that it will help them, Nitin Patel, deputy chief minister said last week.
The opposition Congress party has also criticised PepsiCo for suing the farmers.
"Pepsi’s decision to take Gujarat’s potato grower farmers to court is ill-advised and brazenly wrong," senior Congress party leader Ahmed Patel, who comes from Gujarat, said in a Tweet.
The All India Kisan Sabha, or All India Farmers' Forum, has asked the Indian government to protect the farmers and also called for a boycott of Lay's chips and PepsiCo's other products.
PepsiCo is the second large US company to face major patent infringement issues in India.
Stung by a long-standing intellectual property dispute, seed maker Monsanto, now owned by German drugmaker Bayer AG , withdrew from some businesses in India over a cotton-seed dispute with farmers.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.